Real-World Evaluation and Translational Research on Trastuzumab Biosimilar

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035874

Enrollment

Unknown

Registered

2020-08-19

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer, gastric cancer and other HER2-positive malignant tumors

Interventions

Case series:Trastuzumab biosimilar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Her2-positive Chinese patients with malignant tumors treated with trastuzumab biosimilar; Patients who agreed to participate in the study and signed informed consent;

Exclusion criteria

Exclusion criteria: Refuse to be enrolled in this study or cooperate with follow-up

Design outcomes

Primary

Measure	Time frame
efficacy;safety;econimics;	—

Secondary

Measure	Time frame
quality of life;compilance;accessibility;	—

Countries

China

Contacts

Public ContactQING ZHAI

Fudan University Shanghai Cancer Center

zhaiqing63@126.com+86 021 64431945

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026